Authors: Noble S, Lloyd A, Dewilde S, Reimer E, Lee A
Published in: Annals of Oncology. 2016 Oct;27(suppl_6):VI356
Abstract
Background: Venous thromboembolism (VTE), is common in cancer patients and its treatment is associated with a high risk of recurrent VTE (rVTE) and bleeding. The initial VTE is known to reduce health-related quality of life (HRQL) but little is known about the impact of later events and complications. The CATCH trial investigated the benefits of extended anticoagulation for the prevention of rVTE events in 900 patients with active cancer and acute VTE from 32 countries. We present analyses of the trial data here to describe the impact of rVTE and bleeding events on HRQL.
Methods: EQ-5D-3L data were collected at baseline and every month for seven months. EQ-5D scores range from 1.0 (full health) through 0 (dead) and down to -0.594. Analyses were designed to control for effects of covariates such as age, gender, metastatic status, primary site of cancer, ECOG status, and history of VTE, while estimating the specific impact of a rVTE or bleeding event. Mixed models for repeated measures were designed to accommodate correlations in the dataset through different specifications of the variance-covariance matrices. The impact of an event was reflected when it occurred within ±2 weeks from a planned data collection point.
Results: HRQL data were available from 883 patients. A total of 76 rVTE and 141 bleeding events occurred during follow-up, which was reflected in 183 HRQL assessments.
she-consulting.be 